CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Lyprinol +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01504646
NCT01504646N/ACompleted
CompareCT.gov

Randomized Controlled Trial of Marine Lipid Fraction PCSO-524™ on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction in Asthma

Indiana University·interventional·Posted Jan 5, 2012·Updated Oct 23, 2018

In Brief

A clinical study evaluating Lyprinol and Placebo (Olive Oil) for Asthma and Exercise-Induced Bronchoconstriction. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The primary aim of this study will be to evaluate the effects of Lyprinol® supplementation on airway inflammation and the bronchoconstrictor response to dry air hyperpnea in individuals with asthma. The investigators hypothesize that Lyprinol® supplementation, compared to placebo, will significantly attenuate airway inflammation and hyperpnea-induced bronchoconstriction in asthmatic individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Exercise-Induced Bronchoconstriction
CountriesUnited States
CollaboratorsPharmalink

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 5, 2012
Enrollment StartJan 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.5 years ago

Interventions

Lyprinoldietary

8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks

Placebo (Olive Oil)dietary

8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks